Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia

Abstract

Myocardial ischemia (MI) remains one of the leading causes of death worldwide.Angiogenic therapy with the vascular endothelial growth factor (VEGF) is a promising strategy to overcome hypoxia and its consequences. However, from the clinical data it is clear that fulfillment of the potential of VEGF warrants a better delivery strategy. On the other hand, the compelling evidences of the role of oxidative stress in diseases like MI encourage the use of antioxidant agents. Coenzyme Q 10 (CoQ 10 ) due to its role in the electron transport chain in the mitochondria seems to be a good candidate to manage MI but is associated with poor biopharmaceutical properties seeking better delivery approaches.The female Sprague Dawley rats were induced MI and were followed up with VEGF microparticles intramyocardially and CoQ 10 nanoparticles orally or their combination with appropriate controls. Cardiac function was assessed by measuring ejection fraction before and after three months of therapy.Results demonstrate significant improvement in the ejection fraction after three months with both treatment forms individually; however the combination therapy failed to offer any synergism. In conclusion, VEGF microparticles and CoQ 10 nanoparticles can be considered as promising strategies for managing MI.

Effect of Local Sustainable Release of BMP2-VEGF from Nano-Cellulose Loaded in Sponge Biphasic Calcium Phosphate on Bone Regeneration

“…[17][18][19][20][21][22] Bone regeneration process is accomplished by the active participation of different growth factors.…”

Nano- and Microscale Delivery Systems for Cardiovascular Therapy

“…Longer retention of the microparticles coupled with sustained release of VEGF and increased vasculogenesis aided in positive remodeling of the heart. In another study, co-administration of angiogenic VEGF and antioxidant CoQ10 delivering PLGA Resomer ® microparticles (5 μm) and nanoparticles, respectively, in rat model of myocardial infarction was surprisingly not more functionally benefi cial than individual treatments [ 77 ]. This study warrants an investigation on different times of administration and any neutralizing effects of VEGF and CoQ10 on each other.…”

Heart regeneration after myocardial infarction using synthetic biomaterials

“…Interestingly, CQ10-NPs showed better outcomes than commercial CQ10, what was attributed to the ability of NPs to improve oral bioavailability and to the sustained release of the encapsulated CoQ10. Unfortunately, combined treatment failed to offer synergy, and no EF improvements could be observed [125]. In another study, we successfully delivered FGF-1 and NRG-1 to the ischemic tissue using PLGA MPs (5 µm), administering a final amount of 1740 ng of FGF and/or 1300 ng of NRG in treated animals.…”